News

Researchers compared the cost of treatment for different chimeric antigen receptor T-cell therapies as third-line or later treatment for patients with relapsed or refractory large B-cell lymphoma in the US.

NCCN recently published updated recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL) and histologic transformation of indolent lymphomas to DLBCL.

Researchers studied data on the outcomes of patients who received a BTKi in first or second line but subsequently discontinued treatment.

In July 2023, the FDA approved dostarlimab-gxly with carboplatin and paclitaxel for the treatment of advanced endometrial cancer in adult patients.

A recent study by Aaron T. Gerds, MD, Cleveland Clinic Taussif Cancer Institute, and colleagues evaluated HCRU, costs, and overall survival for patients with myelofibrosis who receive ruxolitinib treatment.

Researchers investigated how socioeconomic status, race, and primary language spoken at home can affect time to diagnosis for patients with diffuse large B-cell lymphoma (DLBCL).

Researchers conducted a study on the number of patients with endometrial cancer who received adjuvant radiation treatment in the states that implemented further Medicaid expansion.

In a recent study, Soyon Lee, MPH, and John D. Seeger, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, examined the association between race and cancer-specific survival among patients with diffuse large B-cell lymphoma.

Two recent retrospective studies by Toby Eyre, MD, Oxford Cancer and Hematology Centre, Oxford University NHS Foundation Trust, Oxford, UK, and colleagues, and Anthony Mato, MD, MSCE, Director of the CLL Program, University of Pennsylvania,...

Edward R. Scheffer Cliff, MBBS, MPH, Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, and colleagues recently evaluated...